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Background: Robust ERK1/2 activity, which frequently results from KRAS mutation, invariably occurs in pancreatic
ductal adenocarcinoma (PDAC). However, direct interference of KRAS signaling has not led to clinically successful
drugs. Correct localization of RAF is regulated by the scaffold protein prohibitin (PHB) that ensures the spatial
organization between RAS and RAF in plasma membranes, thus leading to activation of downstream effectors.
Methods: PHB expression was analyzed in human pancreatic cancer cell lines, normal pancreas, and PDAC tissue.
Furthermore, genetic ablation or pharmacological inhibition of PHB was performed to determine its role in growth,
migration, and signaling of pancreatic cancer cells in vitro and in vivo.
Results: The level of PHB expression was crucial for maintenance of oncogenic ERK-driven pancreatic tumorigenesis.
Additionally, rocaglamide (RocA), a small molecular inhibitor, selectively bound to PHB with nanomolar affinity to
disrupt the PHB-CRAF interaction by altering its localization to the plasma membrane. Consequently, there was
an impairment of oncogenic RAS-ERK signaling, thereby blocking in vitro and in vivo growth and metastasis of
pancreatic cancer cells that were addicted to RAS-ERK signaling. More importantly, RocA treatment resulted in a
significant increase of the lifespan of tumor-bearing mice without any detectable toxicity.
Conclusions: Blockade of the PHB scaffold-CRAF kinase interaction, which is distinct from direct kinase inhibition,
may be a new therapeutic strategy to target oncogenic ERK-driven pancreatic cancer.
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The almost universal lethality of pancreatic ductal adeno-
carcinoma (PDAC) has led to intensive study of the genetic
mutations responsible for its initiation and progression
[1-3]. The most common oncogenic mutations associated
with all PDAC stages occur in the KRAS gene, indicating
that this gene is the primary initiator of PDAC [4]. How-
ever, RAS is an intractable therapeutic target and RAS
inhibitors have not been successful in clinical trials. There-
fore, targeting downstream kinases in the pathway such as
RAF and MEK may be a new approach [5,6]. Unfortu-
nately, the structures of the catalytic domains of various* Correspondence: zschen@tjh.tjmu.edu.cn; hefantj@gmail.com
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unless otherwise stated.kinases are highly similar and many “specific” inhibitors
target multiple kinases rather than their intended target
[7]. Additionally, cancer cells rapidly acquire resistances
against kinase inhibitors. Thus, novel therapeutics targeting
regions outside the kinase domain have become much
more necessary for components of the RAS-RAF-ERK
pathway.
Intracellular scaffold proteins mediate protein-protein
interactions as well as spatial and temporal regulation to
generate signal specificity, which ultimately controls cellu-
lar behavior [8,9]. Prohibitin (PHB), a flagship member of
the Band-7 family of proteins, is highly conserved, ubi-
quitously expressed, and localizes to the mitochondria,
cytosol, nucleus, and plasma membrane [10-13]. Notably,
PHB is a scaffold protein required for the interaction
between RAS and RAF at the plasma membrane, thus lead-
ing to RAS-mediated activation of RAF and downstreamd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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silenced HeLa cells exhibit reduced spreading and increased
intercellular adhesion, forming tiny islands of densely
packed cells [15]. We observed that the pancreatic cancer
cell line Capan-2 exhibits similar tiny islands of densely
packed cells. Therefore, we hypothesized that deficient
PHB expression may exist in Capan-2 cells. In addition,
whether PHB plays any role in RAS-ERK-driven pancreatic
cancer remains undetermined.
Rocaglamide (RocA), a naturally occurring compound,
has a unique cyclopenta [b] benzofuran skeleton and is
isolated from the medicinal plants belonging to genus
Aglaia (family Meliaceae) [16], which are traditionally
used in folk medicine for the treatment of coughs, injuries,
asthma, and inflammatory skin diseases. More recently,
Polier et al. [17] carried out affinity chromatography-
coupled mass spectrometry to identity PHB as the direct
target of RocA in leukemic cells. Importantly, they also
revealed the mechanism in which binding of RocA to
PHB prevents CRAF-PHB interactions, thus leading to
impaired ERK1/2 activation in leukemic cells. Therefore,
RocA may be used to target protein-protein interactions
rather than the catalytic kinase domain.Figure 1 Expression of PHB in pancreatic cancer cells and tissue. A. M
analysis of PHB mRNA expression in AsPC-1 and Capan-2 cells. β-actin was
and Capan-2 cells. α-tubulin was used as a control. D. Confocal microscopi
Nuclei were counterstained with DAPI. Scale bars, 25 μm. E. Quantification
triplicate samples, *P < 0.01. F. Representative images of PHB expression in
of PHB expression in PDAC and normal pancreas tissues. Tumors were blin
samples and n = 46 PDAC tissue samples). Results are representative of threIn the present study, we unravel a new therapeutic
paradigm to inhibit RAS-driven pancreatic tumors by
blocking the interactions of PHB scaffold-CRAF kinase.
Furthermore, RocA suppresses ERK activity and blocks
in vitro and in vivo growth and metastasis of pancreatic
cancer cells that are addicted to the ERK pathway.
Thus, the regulation of RAS-RAF-ERK pathway by
targeting the PHB-CRAF interaction introduces a novel
potential therapeutic approach for ERK-driven pancreatic
cancer.
Results
Expression and localization of PHB in pancreatic cancer
cells and tissue
To investigate the role of PHB in pancreatic cancer cells,
we first chose two human pancreatic cancer cell lines,
AsPC-1 (high malignancy) and Capan-2 (low malig-
nancy). Interestingly, AsPC-1 cells grew as single cells
(Figure 1A, left), whereas Capan-2 cells exhibited tiny
islands of densely packed cells (Figure 1A, right). Add-
itionally, AsPC-1 cells exhibited much higher growth
and migration capacities than those of Capan-2 cells
(Additional file 1: Figure S1A,B). RT-PCR showed aorphology of AsPC-1 and Capan-2 cells. Scale bar, 25 μm. B. RT-PCR
used as a control. C. Immunoblot analysis of PHB protein in AsPC-1
c images of the localization of PHB (red) in AsPC-1 and Capan-2 Cells.
of the fluorescence intensity in (D). Values are the means ± SD of
PDAC and normal epithelial tissues. Scale bar, 50 μm. G. Quantification
dly scored based on the strength of PHB staining (n = 11 normal tissue
e independent experiments.
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higher expression in AsPC-1 cells than that in Capan-2
cells (Figure 1B and Additional file 1: Figure S2A). In agree-
ment with RT-PCR data, immunoblot analysis also demon-
strated high expression of PHB protein in AsPC-1 cells, but
little expression in Capan-2 cells (Figure 1C and Additional
file 1: Figure S2B). Intriguingly, localization of PHB in
AsPC-1 cells was mainly in the plasma membrane and
cytosol, whereas its localization was uniform in Capan-2
cells (Figure 1D,E). This result indicated that the observed
phenotypes may correlate with the expression and localiza-
tion of PHB protein. Therefore, AsPC-1 cells were chosen
to investigate the biological properties of PHB in pancre-
atic cancer both in vitro and in vivo.
We next assessed PHB expression in pancreatic tissue.
PHB protein was weakly expressed in 63.6% of normal
pancreas samples (n = 11) (Figure 1F,G). However, PHB
protein was strongly expressed in 58.7% of PDAC samples
(n = 46) (Figure 1F,G and Additional file 1: Figure S3).
Taken together, these results show that PHB, which
becomes more pronounced with pancreatic cancer malig-
nancy, may serve as a therapeutic target in pancreatic
cancer.Figure 2 PHB is indispensable for EGF-induced ERK activation in panc
levels in AsPC-1 and Capan-2 cells. α-tubulin was used as a loading control
or control (siCon) siRNAs. At 48 h post-transfection, cells were treated with
using the indicated antibodies. p-ERK1/2 was detected as an activation ma
images of the localization of PHB (red) and p-ERK1/2 (green). AsPC-1 cells w
After 48 h of transfection, cells were stimulated with EGF (50 ng/ml) for 15
p-ERK1/2. Nuclei were counterstained with DAPI. Scale bars, 10 μm. ResultsPHB is indispensable for EGF-induced ERK activation in
pancreatic cancer cells
The duration of ERK activity is a crucial factor in diverse
biological processes that determine cell fate decisions
[18]. ERK is phosphorylated and activated by MEK in re-
sponse to growth factor stimulation, and then activated
ERK phosphorylates and activates nuclear targets to up-
regulate immediate-early genes [19]. Therefore, we deter-
mined the expression levels of p-ERK1/2 in AsPC-1 and
Capan-2 cells. Intriguingly, the phosphorylation status of
ERK2 was much higher than that of ERK1 in AsPC-1 cells,
and this phenomenon was completely converse in Capan-2
cells (Figure 2A). This observation suggests distinct roles
of ERK1 and ERK2 in the regulation of cell behavior in
AsPC-1 and Capan-2 cells.
To test whether PHB is required for the ERK pathway,
we validated a siRNA against PHB (siPHB) in AsPC-1
and Panc-1 cells by quantitative real-time PCR. The re-
sults showed that siPHB reduced the PHB mRNA level by
about 80% compared with that using control siRNA
(siCon) (Additional file 1: Figure S4A,B). Furthermore,
we checked the phosphorylation status of ERK1/2 in
siPHB-transfected AsPC-1 and Panc-1 cells. As expected,reatic cancer cells. A. Immunoblot analysis of PHB and p-ERK1/2
. B. AsPC-1 and Panc-1 cells were transfected with PHB-specific (siPHB)
EGF (50 ng/ml) for 15 min and then subjected to immunoblot analysis
rker and α-tubulin as the loading control. C. Confocal microscopic
ere transfected with PHB-specific (siPHB) or control (siCon) siRNAs.
min. AsPC-1 cells were incubated with antibodies specific for PHB and
are representative of three independent experiments.
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(EGF) caused an increase of ERK1/2 phosphorylation
(Figure 2B,C), whereas silencing of PHB expression
strongly suppressed the EGF-induced phosphorylation
of ERK (Figure 2B,C). This finding suggested specific
involvement of PHB in the RAS-RAF-ERK pathway.
Moreover, a similar result was obtained in Panc-1 cells
(Figure 2B), indicating general inhibition of ERK activation
by PHB depletion. Thus, these results clearly indicate that
PHB is required for EGF-induced ERK1/2 activation in
pancreatic cancer cells.
RocA disrupts the ERK pathway by targeting the
CRAF-PHB interaction in AsPC-1 cells
The oncogenic RAS-ERK pathway is a key node for
cellular proliferation signals and has been the focus of
substantial drug discovery efforts in many cancers [20-23].
A previous study has indicated that RocA suppresses the
ERK pathway in leukemic cells [24]. To confirm that the
anti-tumor effect of RocA is indeed caused by suppression
of the ERK pathway, we examined the effect of RocA on
ERK activity in AsPC-1 cells (Figure 3E). The resultsFigure 3 RocA disrupts the RAS-ERK pathway by targeting the CRaf-P
AsPC-1 cells were treated with RocA at various concentrations or time peri
by immunoblot analysis. ERK1 and α-tubulin were used as controls. C. Anal
of RocA or DMSO. AsPC-1 cells were treated with RocA (100 nM) or DMSO
fractions were prepared and then subjected to immunoblot analysis with t
of activity and α-tubulin as the loading control. D. Immunoprecipitation of
treatment with RocA (100 nM) or DMSO. E. Confocal microscopic images o
treated with RocA (100 nM) or DMSO for 4 h and then stimulated with EGF (5
for PHB or p-ERK1/2. Nuclei were counterstained with DAPI. Scale bars, 10 μmshowed significant dose-dependent inhibition of the phos-
phorylation status of ERK1/2 (Figure 3B). Importantly,
RocA showed very strong time-dependent suppression of
ERK1/2 activities (Figure 3B).
PHB was previously shown to be required for mem-
brane association and activation of CRAF [15]. Therefore,
we examined whether RocA affects PHB-CRAF mem-
brane association in AsPC-1 cells. To this end, cell
membrane and cytosol fractions were prepared from
AsPC-1 cells treated with Roc-A or DMSO to analyze the
localization of PHB and CRAF. Immunoblot analysis
showed significant reduction of CRAF, particularly phos-
phorylated CRAF (pSer338), in the membrane fraction
after RocA treatment (Figure 3C). Notably, RocA also sig-
nificantly reduced the levels of PHB in the membrane
fraction, indicating that binding of RocA to PHB may also
interfere with PHB membrane association. However,
RocA did not influence membrane localization of RAS
(Figure 3C). Indeed, immunoprecipitation analysis sug-
gested that RocA substantially decreased the amounts of
total CRAF bound to PHB in AsPC-1 cells (Figure 3D).
Notably, confocal microscopic analysis showed thatHB interaction in AsPC-1 cells. A. Chemical structure of RocA. B.
ods as indicated and then the activation status of ERK was examined
ysis of PHB-CRAF membrane localization in AsPC-1 cells in the presence
for 16 h. Whole cell lysates as well as cell membrane and cytosol
he indicated antibodies. Phospho-CRAF (pSer338) was used as marker
PHB protein and associated CRAF from AsPC-1 cells following 4 h of
f the localization of PHB (red) and p-ERK1/2 (green). AsPC-1 cells were
0 ng/ml) for 15 min. AsPC-1 cells were incubated with antibodies specific
. Results are representative of three independent experiments.
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led to a loss of plasma membrane localization and ran-
dom redistribution of PHB (Figure 3E). This observation
indicates that inhibition of the PHB-CRAF interaction by
RocA leads to the loss of spatial organization of PHB in
AsPC-1 cells. Collectively, these results further demon-
strate that RocA blocks the RAS-CRAF-ERK signaling
pathway by disruption of the PHB-CRAF interaction in
pancreatic cancer.
RocA mimics the effect of PHB knockdown on
epithelial-mesenchymal transition (EMT) markers and
reverses the EMT phenotype in AsPC-1 cells
The oncogenic RAS-RAF-ERK pathway confers epithelial
cells with critical motile and invasive capacities during car-
cinoma progression, often by promotion of EMT [25,26].
To further investigate the role of PHB in EMT, the effects
of PHB siRNA and RocA on EMT markers were assayed
in AsPC-1 cells. First, we detected EMT markers in
AsPC-1 and Capan-2 cells (Figure 4A). Knockdown of
PHB in AsPC-1 cells by siRNA resulted in upregulation ofFigure 4 RocA mimics PHB-knockdown effects on EMT markers and r
and then subjected to immunoblot analysis with the indicated antibodies.
(siCon) siRNAs. After 48 h of transfection, the cells were lysed and subjecte
were treated with RocA (100 nM) or DMSO for 16 h, and then subjected to
changes of PHB-knockdown AsPC-1 cells (B) and RocA-treated AsPC-1 cells
Results are representative of three independent experiments.E-cadherin and β-catenin and downregulation of vimentin
(Figure 4B). Similar to the effect of PHB knockdown, treat-
ment of AsPC-1 cells with RocA showed the same results
(Figure 4C).
Activated ERK2 directly phosphorylates Snail, leading
to nuclear accumulation, reduced ubiquitylation, and an
increased protein half-life of Snail, and then promotion
of breast cancer cell invasion and migration in vitro and
metastasis in vivo [27]. Another study has shown clear
increases of ZEB1 and ZEB2 protein levels by ERK2 but
not ERK1 [28]. To further investigate the molecular
basis of ERK-regulated EMT, we detected the levels of
Snail1, ZEB1, and transcription factors known to regu-
late EMT which act downstream of ERK1/2. Interest-
ingly, we observed similar results in PHB-silenced and
RocA-treated AsPC-1 cells (Figure 4B,C).
AsPC-1 cells lacking PHB expression showed defective
migration (Figure 4D), indicating that the formation of
clusters is the consequence of reduced motility of cells
that lack high levels of PHB. Notably, AsPC-1 cells treated
with RocA formed cell clusters similar to those formed byeverses EMT in AsPC-1 cells. A. AsPC-1 and Capan-2 cells were lysed
B. AsPC-1 cells were transfected with PHB-specific (siPHB) or control
d to immunoblot analysis with the indicated antibodies. C. AsPC-1 cells
western blot analysis with the indicated antibodies. D. Morphological
(C) treated with control siRNAs (siCon) or DMSO. Scale bars, 25 μm.
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together, RocA mimics the effect of PHB knockdown on
EMT marker expression and reverses the EMT phenotype
in AsPC-1 cells.
RocA selectively diminishes the viability of
PHB-dependent pancreatic cancer cells in vitro
and inhibits their migration in vitro and in vivo
To characterize the action of RocA on pancreatic cancer
cell growth, AsPC-1 and Panc-1 cells were treated with
RocA (100 nM) or DMSO for 16 h and then applied to
CCK-8 assays. RocA markedly impaired the growth of
AsPC-1 and Panc-1 cells without affecting Hs 578Bst or
L02 cells as controls (Figure 5A,B). Interestingly, Capan-2
cells did not show any detectable toxicity in the presence
of RocA (Additional file 1: Figure S5), suggesting deficient
expression of PHB in Capan-2 cells may rescue the effects
of RocA. Additionally, RocA impaired the migration of
AsPC-1 and Panc-1 cells (Figure 5C).
To investigate the effect of RocA on metastasis, we
established an orthotopic xenograft model in mice using
AsPC-1 cells. At 1 week after orthotopic implantation of
AsPC-1 cells into severe combined immunodeficient
(SCID) mice, RocA (5 mg/kg body weight) was adminis-
trated via intraperitoneal injection daily for 3 weeks. As aFigure 5 RocA selectively diminishes the viability and migration of KR
RocA-treated AsPC-1 and Panc-1 cells. Values are the means ± SD of triplica
and L02 cells. Values are the means ± SD of triplicate samples, *P < 0.01. C.
RocA (50 or 100 nM). The plot shows the quantification of cells that passed
the means ± SD of triplicate samples, *P < 0.01. Scale bars, 25 μm. D. Effect
model. AsPC-1 cells were orthotopically injected into the pancreas of mice
(5.0 mg/kg, n = 3) or the vehicle (1% DMSO in olive oil, n = 3) was administ
and livers of mice were collected and processed for H&E staining. The num
mice. Arrows indicate tumor foci. T, tumor. Values are the means ± SD of trresult, treatment with RocA significantly suppressed can-
cer metastasis to the lung and liver in mice (Figure 5D).
Histological analysis of the lung and liver revealed that
dissemination of cancer cells was absent in tissue sections
from RocA-treated mice, but an abundance of cancer cells
were observed in vehicle-treated mice (Figure 5D). Com-
parison of the survival curve of RocA-treated mice with
that of vehicle-treated mice showed that RocA treatment
significantly prolonged the survival of tumor-bearing mice
(Additional file 1: Figure S6A,B). Taken together, RocA
impairs the migration of pancreatic cancer cells in vitro
and in vivo.
RocA suppresses in vivo growth of tumor xenografts
To further evaluate the anti-tumor activity of RocA, we
administered RocA to SCID mice bearing subcutaneous
AsPC-1 tumor cell xenografts and monitored the tumor
growth rate. RocA was administrated by intraperitoneal
injection once per day. As a result, RocA significantly
suppressed tumor growth compared with that in the con-
trol group. Tumor volumes in the RocA-treated group
were 37 ± 8% of those in the control group (Figure 6A,B).
Intriguingly, RocA treatment neither caused any loss of
body weight nor exhibited apparent signs of toxicity in
mice during the treatments (Figure 6C), suggesting thatAS-mutated pancreatic cancer cells. A. Viability of DMSO- and
te samples, *P < 0.01. B. Viability of DMSO- and RocA-treated Hs 578Bst
Transwell migration assays of AsPC-1 and Panc-1 cells treated with
through the filters relative to DMSO that was set to 100%. Values are
of RocA on pancreatic cancer metastasis in an orthotopic xenograft
(n = 6) as described in the Methods. At 1 week post-implantation, RocA
rated via daily intraperitoneal injection for 4 weeks. Then, the lungs
ber of tumor foci was counted in the lungs and livers of sacrificed
iplicate samples, *P < 0.01. Scale bars, 50 μm.
Figure 6 RocA suppresses in vivo tumor growth in a xenograft model. Subcutaneously established AsPC-1 cell-derived tumors in SCID mice
were treated with the vehicle (1% DMSO in olive oil, n = 6) or RocA (5.0 mg/kg, n = 5) via daily intraperitoneal injection for 48 days. The tumor
volume (A, B) and body weight (C) were monitored twice per week for 28 days. Values are the means ± SD of triplicate samples, *P < 0.01. Scale
bar, 1 cm. D. Survival of mice with established tumor burden randomized to receive RocA or vehicle by intraperitoneal injection. E. Median
survival of the mice in (D). Statistical significance was calculated by the log-rank test. Data are shown as the means ± SD. F. Histological analysis
of tumors from (A, B) was performed by H&E staining and examining Ki-67 and cyclin D1 expression to compare cell proliferation in RocA- and
vehicle-treated tumors. Scale bars, 50 μm. G. Quantification of Ki-67- and cyclin D1-positive cells in (F). Values are the means ± SD of triplicate
samples, *P < 0.01.
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RocA-treated mice eventually died from the pancreatic
tumors, treatment with RocA significantly extended
their lifespan compared with that of vehicle treatment
(Figure 6D,E).
Next, we investigated the effect of RocA on cell prolif-
eration in vivo by hematoxylin and eosin (H&E) staining
and examining Ki-67 and cyclin D1 expression in tumor
tissues harvested from vehicle- and RocA-treated mice.
H&E staining showed a compact mass of epithelial cells invehicle-treated mice, whereas RocA-treated tumors exhib-
ited loose epithelial cell aggregates with a higher number
of interspersed mesenchymal cells (Figure 6F, left). In
addition, RocA treatment resulted in a 3.2-fold decrease of
Ki-67-positive cells in tumor sections from RocA-treated
mice compared with that in vehicle-treated mice (Figure 6F,
middle and 6G, upper). Furthermore, we found a 4.1-fold
decrease of cyclin D1-positive cells in tumor sections from
RocA-treated mice relative to that in vehicle-treated
mice (Figure 6F, right and 6G, lower). Therefore, RocA is
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AsPC-1 cell-derived tumors in vivo.
Discussion
The RAS-RAF-ERK signaling pathway has been intensely
researched because of its central role in cancer cell prolifer-
ation, survival, invasion, and metastasis [21,29,30]. How-
ever, the small G-protein RAS appears to be an intractable
therapeutic target. Alternatively, downstream kinases in the
pathway can be targeted, such as RAF and MEK. Although
inhibitors of RAF and MEK have shown therapeutic value,
tumor resistances counteract their effectiveness [31-33].
Therefore, targeting scaffold proteins such as PHB may be
a valid downstream target of RAS.
Here, we represent a new strategy for combating onco-
genic RAS-ERK signaling pathway by targeting the PHB-
CRAF interaction in pancreatic ductal adenocarcinoma.
Considering that PHB forms a signaling complex with
CRAF to regulate RAF-MEK-ERK pathway, we demon-
strated that PHB was highly expressed in human pancre-
atic cancer and depletion of PHB reduced in vitro invasion
of RAS-driven cancer cells. In addition, we found that de-
pletion of PHB suppressed ERK activity. Furthermore, ERK
activity was blocked by RocA in RAS-driven cancer cells.
RocA also suppressed the growth and invasion of these
cells in vitro and inhibited the growth of tumor xenografts
in SCID mice. Notably, no such effects were observed in
normal epithelial cells, demonstrating the specificity of this
response. To assess the consequences of long-term RocA
treatment, we found that RocA extended the lifespan of
these animals with a notable lack of toxicity compared with
that of animals treated with the vehicle only.
Thus, RocA suppressed ERK activity and inhibited
in vitro and in vivo growth and migration of cancer cells,
which are dependent on the ERK pathway. These results
indicated that the PHB scaffold function is essential in
ERK pathway-driven pancreatic cancer cells and vali-
dated PHB as a therapeutic target. More importantly,
RocA was relatively nontoxic in PHB-deficient cancer
and normal cells, suggesting that the scaffold function of
PHB in the ERK pathway is dispensable in these cells.
These observations suggest that ERK-driven cancer cells
are particularly sensitive to both the levels and fidelity of
ERK signaling, and that PHB plays a key role in ensuring
that signaling is maintained at optimal levels. This infer-
ence may be why these cells are sensitive to disruption
between CRAF and PHB by RocA.
Although our work provides a strong case for targeting
PHB by RocA, it remains to be determined whether this
known RocA activity may contribute to the overall effect
of RocA on survival of pancreatic tumor cells in vivo
and in vitro.
RocA has been reported to inhibit translation initiation
to block HSF1 activation by stimulating an interaction ofRNA with eIF4A helicase [34]. However, the RAS-RAF-
ERK pathway is a key pathway that regulates protein syn-
thesis and tumor survival [35,36]. RocA does not directly
disrupt the translational machinery, but it inhibits the
ERK pathway to prevent eIF4E phosphorylation and
subsequently suppress translation [37,38]. Therefore, the
translation inhibition and the degree to which their roles
overlap complement or antagonize each other in modulat-
ing the pathway remain elusive. Additionally, it is unclear
if RocA will succumb to the same pitfalls as other RAF-
targeting therapies. Clearly, unravelling the complexity of
disrupting PHB function will be challenging. However, our
study represents a compelling argument for future investi-
gating PHB in oncogenic pathway as a drug target.
Conclusions
In summary, targeting the PHB-CRAF interaction repre-
sents a potential new avenue for the treatment of pancre-
atic cancer. This new approach could be an important
supplement therapy and may provide mechanistic insight
into the molecular basis of RAS-RAF-ERK pathway in
pancreatic cancer. Thus, RocA treatment as a new tar-
geted therapy is a promising approach for improving the
current therapeutic strategies and overcoming resistances
of kinase inhibitors, and should be investigated in future
preclinical and clinical studies.
Methods
Reagents
Antibodies against PHB, ERK1, CRAF, RAS, Ki-67, and
cyclin-D1 were obtained from Abcam (Cambridge, UK).
An anti-α-tubulin antibody was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). EGF, an Epithelial Mesen-
chymal Transition Antibody Sampler Kit, and antibodies
against phosphorylated forms of ERK1/2 and CRAF
(Ser338) were purchased from Cell Signaling Technology
(Danvers, MA). Cell culture reagents were purchased from
GIBCO/Invitrogen (Carlsbad, CA). Specific siRNA against
PHB and control siRNA were purchased from Qiagen
(Valencia, CA). RocA (>98% pure) was procured from
Enzo Life Sciences (Lörrach, Germany). All chemicals were
purchased from Sigma Aldrich (St. Louis, MO) unless indi-
cated otherwise.
Cell lines, culture conditions, and clinical specimens
Pancreatic cancer cell lines AsPC-1, Capan-2, and Panc-1
were obtained from the American Type Culture Collec-
tion (Rockville, MD). The cells were cultured in RPMI
1640 medium supplemented with 10% fetal calf serum,
penicillin (100 U/ml), and streptomycin (100 μg/ml) in a
humidified incubator containing 5% CO2 at 37°C. The
normal human breast epithelial cell line Hs 578Bst and
normal human liver cell line L02 were purchased from
Shanghai Cell Bank (Shanghai, China). These cells were
Luan et al. Molecular Cancer 2014, 13:38 Page 9 of 11
http://www.molecular-cancer.com/content/13/1/38cultured in Dulbecco's modified Eagle's medium supple-
mented with 10% fetal calf serum, penicillin (100 U/ml),
and streptomycin (100 μg/ml) in a humidified incubator
containing 5% CO2 at 37°C. AsPC-1 and Capan-2 cells
were serum starved for 4–6 h before stimulation with
EGF at a final concentration of 50 ng/ml for 15 min. Tis-
sue samples were collected from patients during pancre-
atic resections for PDAC (n = 46). Normal pancreatic
tissue samples were obtained through an organ donor
procurement program when there was no suitable recipi-
ent for pancreatic transplantation (n = 11). Pancreatic tis-
sues were immediately stored at –80°C or formalin-fixed
and paraffin-embedded for histological analysis. The use
of human tissue was approved by the local ethics commit-
tee (Tongji Medical College, China) and written informed
consent was obtained from patients prior to surgery.
RT-PCR and quantitative real-time PCR
At the indicated time points, total RNA was harvested
from cells by treatment with TRIzol (Invitrogen) according
to the manufacturer’s protocol. For RT-PCR analysis, total
RNA (1 μg) was used as a template for cDNA synthesis
with a reverse transcription kit (Fermentas). Equal
amounts of cDNA were used in PCR analyses. The follow-
ing primers were used in this study. PHB: forward, 5′-
CTGCCTTATATAATGTGGATGCTG-3′ and reverse,
5′-GCTCTCTCTGGGTGATTAGTTCTC-3′; β-actin:
forward, 5′-AGTGTGACGTCGACATCCGC-3′ and re-
verse, 5′-GACTCGTCGTACTCCTGCTT-3′. For quanti-
tative real-time PCR analysis, the relative amount of PHB
mRNA was determined using a Quantitect™ SYBR® Green
RT-PCR Kit (Qiagen) following the manufacturer’s in-
structions. The expression level of PHB mRNA was
normalized against the internal standard, GAPDH. The
following primers were used in the analyses. PHB: for-




Immunoprecipitation and immunoblot analysis
Cells were washed twice with ice-cold PBS and then
lysed with ice-cold lysis buffer. Lysates were kept on ice
for 30 min and then centrifuged at 17,000 g for 15 min
at 4°C. Equal amounts of proteins were used for immu-
noprecipitation of PHB by overnight incubation (at 4°C
with gentle rocking) with specific antibodies and then
protein G-agarose. The agarose beads were washed five
times with washing buffer, resuspended in 2× Laemmli
buffer, and then boiled for 5 min. For western blot-
ting analysis, equal amounts of proteins were sepa-
rated by SDS-polyacrylamide gel electrophoresis and
then transferred onto polyvinylidene difluoride mem-
branes (Millipore). The membranes were blocked with5% bovine serum albumin (BSA) in Tris-buffered saline-
Tween 20 for 2 h and then incubated with primary anti-
bodies at 4°C overnight. Immunoreactive proteins were
detected with horseradish peroxidase-conjugated second-
ary antibodies.
Confocal microscopy
Cells were fixed with 4% formaldehyde in PBS for
10 min, washed, and then permeabilized with 0.5% Tri-
ton X-100 for 15 min. The fixed cells were incubated
with 1% BSA in PBS for 60 min and then overnight with
gentle rocking at 4°C with antibodies against PHB and
p-ERK1/2. The cells were washed five times with 1%
BSA and then incubated for 50 min with Alexa Fluor
647-labeled rabbit anti-mouse IgG (H + L) (Abcam) to
detect PHB and Alexa Fluor 488-labeled goat anti-rabbit
IgG (H + L) (Abcam) to detect p-ERK1/2. Nuclei were
counterstained with DAPI. After washing the cells with
PBS and mounting with SlowFade Antifade Kit (Life
Technologies), confocal images were obtained with an
FV-1000 confocal laser scanning microscope (Olympus).
PHB knockdown
Cells were transfected with nonsense siRNA or siRNA
targeting PHB (5′-CAGAAA UCACUGUGAAAUUTT-3′)
using HiPerFect transfection reagent (Qiagen) accord-
ing to the manufacturer’s protocol. Cells were collected
at the indicated time points after transfection for various
assays.
CCK-8 assay
Cells were seeded in 96-well plates at 5 × 103 cells per
well and allowed to adhere for 24 h at 37°C. The cells
were then treated with RocA (100 nM) or DMSO for
16 h. Following the treatments, a CCK-8 solution (10 μl;
Dojindo, Kumamoto, Japan) was added to each well.
After incubation at 37°C for another 2 h, viable cells were
detected by measuring the absorbance at 570 nm using an
EL×800 Absorbance Microplate Reader (Bio-Tek, Seattle,
WA, USA). Cell viability was expressed as the percentage
absorbance of cells treated with RocA compared with that
of DMSO-treated cells.
Transwell migration assay
Cell migration was analyzed using a modified two-
chamber transwell system (BD) following the manufac-
turer’s instructions. Cells were detached by trypsin-EDTA,
washed once with serum-free medium, and then re-
suspended in serum-free medium. Then, 0.5 ml of either
complete culture medium or serum-free medium con-
taining 50 ng/ml EGF was added to each lower chamber.
Cells (1 × 105) were added to each transwell insert and
allowed to migrate for 12 h a 37°C. The cells on the
upper surface of the transwells were removed using
Luan et al. Molecular Cancer 2014, 13:38 Page 10 of 11
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surface were fixed with 4% paraformaldehyde for 10 min
and then stained with a crystal violet solution (0.5% in
water) for 10 min. Cells were counted under a microscope
at 200× magnification.
Subcutaneous and orthotopic xenografts in SCID mice
SCID mice were purchased from HFK Bioscience Ltd
(Beijing, China). Animal experiments were performed in
accordance with relevant institutional and national regu-
lations, and research protocols were approved by the
relevant authorities. AsPC-1 cells (3 × 106) suspended in
a 100 μl mixture of equal volumes of medium and matri-
gel were implanted subcutaneously into the right flank
of 6-week-old female SCID mice. When the tumors had
reached a volume of about 50-70 mm3, the mice were
then randomly divided into two groups. The treatment
group received an intraperitoneal injection of RocA
(5.0 mg/kg in 80 μl olive oil, n = 5), whereas the vehicle
control group received olive oil alone (n = 6). These
treatments were carried out once daily for 48 days.
Tumor volumes and the body weight of animals were
measured twice a week. Tumor volumes (mm3) were
calculated with the following formula: V = LS2/2 (where
L is the longest diameter and S is the shortest diameter).
At the end of experiment, the mice were sacrificed and
the tumors were harvested, fixed in formalin, and em-
bedded in paraffin for tissue sectioning and immunohis-
tochemistry. For orthotopic metastasis assays, AsPC-1
cells (3 × 106) were orthotopically injected into the pan-
creas of mice (n = 6) as described previously [39]. At
1 week post-implantation, RocA (5.0 mg/kg in 80 μl
olive oil, n = 3) or the vehicle (1% DMSO in olive oil,
n = 3) was administrated via intraperitoneal injection
daily for 3 weeks. Then, these mice were sacrificed to
evaluate metastasis to the organs such as the liver
and lung. The metastatic nodules in the right lung and
liver were quantified under a dissecting microscope. An-
other ten mice were subjected to the same treatment. The
survival time of these mice in each group (RocA-treated
group, n = 5; Vehicle control group, n = 5) was monitored.
Immunohistochemistry
Immunohistochemical analysis was performed as described
previously [40] with antibodies against PHB, Ki-67, and
cyclin-D1.
Statistics
Data are representative of at least three independent
experiments or multiple independent mice as indicated.
Statistical analyses were performed by Student’s t-tests
and analysis of variance followed by post-hoc compari-
sons. Kaplan-Meier survival data were reanalyzed using
the log-rank test.Additional file
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